Efficacy and safety of edoxaban for treatment of venous thromboembolism: a subanalysis of East Asian patients in the Hokusai‐VTE trial. (27th August 2015)

• Record Type: Journal Article
• Authors: Nakamura, M.; Wang, Y. Q.; Wang, C.; Oh, D.; Yin, W.‐H.; Kimura, T.; Miyazaki, K.; Abe, K.; Mercuri, M.; Lee, L. H.; Segers, A.; Büller, H.
• Is Part Of: Journal of thrombosis and haemostasis. Volume 13:Number 9(2015:Sep.)
• Page Start: 1606
• Page End: 1614
• Publication Date: 2015-08-27
• Subjects: Thrombosis -- Periodicals; Hemostasis -- Periodicals; Blood coagulation disorders -- Periodicals; 616.1
• DOI: 10.1111/jth.13055
• Languages: English
• ISSNs: 1538-7933

Abstract

<abstract abstract-type="main" id="jth13055-abs-0001"> <title>Summary</title> <sec id="jth13055-sec-0001" sec-type="section"> <title>Background</title> <p>Direct oral anticoagulants have been evaluated for their efficacy and safety in the treatment of venous thromboembolism (VTE), which comprises deep vein thrombosis and pulmonary embolism. The randomized, double‐blind Hokusai‐VTE trial demonstrated that 60 mg of edoxaban once daily following initial heparin treatment is non‐inferior to heparin overlapped with and followed by warfarin for the treatment of VTE, and is associated with significantly fewer bleeding events.</p> </sec> <sec id="jth13055-sec-0002" sec-type="section"> <title>Objectives</title> <p>To assess the efficacy and safety of edoxaban versus warfarin among East Asian patients enrolled in the Hokusai‐VTE trial.</p> </sec> <sec id="jth13055-sec-0003" sec-type="section"> <title>Patients/methods</title> <p>The Hokusai‐VTE trial enrolled 8292 patients from 439 centers worldwide, including 1109 patients from Japan, China, Korea, and Taiwan. The primary efficacy and safety outcomes were symptomatic recurrent VTE and clinically relevant bleeding, respectively.</p> </sec> <sec id="jth13055-sec-0004" sec-type="section"> <title>Results</title> <p>In the overall East Asian population, the primary efficacy outcome of symptomatic recurrent VTE occurred in 16 of 563 (2.8%) patients in the edoxaban group versus 24 of 538 (4.5%) patients in the warfarin group (hazard ratio [HR] 0.64; 95% confidence interval [CI] 0.34–1.19; <italic>P </italic>=<italic> </italic>0.1601). The primary safety outcome of clinically relevant bleeding occurred in 56 of 563 (9.9%) patients in the edoxaban group versus 93 of 538 (17.3%) patients in the warfarin group (HR 0.56; 95% CI 0.40–0.78; <italic>P </italic><<italic> </italic>0.001).</p> </sec> <sec id="jth13055-sec-0005" sec-type="section"> <title>Conclusions</title> <p>Edoxaban is an effective and safer alternative to warfarin in East Asian patients with acute VTE who require anticoagulant therapy, consistent with overall study findings from the Hokusai‐VTE trial.</p> </sec> </abstract>